Drawing for NEURODERM

USPTO serial 79299574

NEURODERM

Reviewed by CopyMark Law Group

Reg. 6358631Status 700Renewal
Filing date
Status date
Registration date
May 25, 2021
Examiner
ADORNO SANTOS, LUZ M.
Law office
TMO LAW OFFICE 111

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with NEURODERM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

A. Tally Eitan

A. Tally Eitan Eitan Mehulal Sadot6480 Calverton Drive, Unit 202,c/o Edna EisemannFrederick, MD 20874

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals, namely, pharmaceutical preparations for use in preventing and treating conditions, diseases, or disorders of the central nervous, neurological, cardiovascular, endocrine, gastric or gastroenteric, hematologic, immunologic, inflammatory, osteologic, or respiratory systems; pharmaceutical preparations for use in prevention and treatment of allergies or allergic responses, metabolic disorders, psychiatric and emotional disorders, infection and infectious diseases, pain; drug delivery kits comprising dressings for medical, surgical, and veterinary use [ ; drug delivery agents, namely, transdermal patches sold with medication for use in the treatment of conditions, diseases or disorders of the central nervous, neurological, cardiovascular, endocrine, gastric or gastroenteric, hematologic, immunologic, inflammatory, osteologic, or respiratory systems ]ACTIVE—
010Medical devices for delivery of medicated and pharmaceutical preparations, namely, implantable drug delivery pumps, drug delivery catheters, drug delivery patches sold without medication, subcutaneous drug delivery pumps, subcutaneous drug delivery patch pumps, refillable drug delivery pumps, and infusion drug delivery pumps; drug delivery device sold empty, namely, syringes, infusion drug delivery pumps; infusion sets; electromagnetic drug delivery apparatus for medical use; medical apparatus, namely, implantable ports; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus and medical instruments for administering fluid, drugs, and nutrition, namely, infusion pumps, patch pumps being adherable subcutaneous drug delivery pumps, wearable medication injectors, wearable subcutaneous drug delivery pumps, and handheld medication injectors; medical syringes; medical devices in the nature of infusion pumps for drug infusion and for monitoring the infusion of drugs with integrated recorded software for transmission and receiving of drug infusion data, data related to the infusion pumps, drug infusion monitoring, filling and emptying of drug vials, and patient's behavior and reaction to drugs, sold as a unit therewith; drug delivery devices, namely, catheters, injection pen needles, injection needles, injection syringes and implantable subcutaneous drug delivery pumps; lancets; medical lancing devices for delivering medication, sold empty; drug eluting stents; bio-absorbable stents; synthetic stent grafts; medical diagnostic apparatus used to detect and measure the level of substances in body fluids; medical apparatus for measuring dosages and delivering pharmaceuticals, namely, infusion drug delivery pumps, subcutaneous drug delivery wearable pumps, subcutaneous drug delivery patch pumps, implantable drug delivery pumps and injection pens; electromedical rehabilitative and pain management products for clinical and home use, namely, electrical nerve and muscle stimulators, ultrasonic stimulators, magnet therapy stimulators and laser therapy stimulators; electronickinetic transdermal drug delivery control unit for the treatment of diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 25, 2026REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jul 30, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 9, 2022INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Feb 9, 2022INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Oct 4, 2021FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 11, 2021FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 11, 2021FIMPFINAL DISPOSITION PROCESSED—
Aug 25, 2021FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 10, 2021LIMELIMITATION FROM THE IB EXAMINED AND ENTERED—
Jun 9, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 9, 2021COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Jun 9, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 25, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 23, 2021LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Mar 22, 2021LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Mar 15, 2021GPNXNOTIFICATION PROCESSED BY IB—
Mar 9, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 9, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 28, 2021LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Feb 24, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Feb 24, 2021OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Feb 17, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 2, 2021ALIEASSIGNED TO LIE—
Feb 2, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 2, 2021XAECEXAMINER'S AMENDMENT ENTERED—
Feb 2, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 2, 2021GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 2, 2021CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 1, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 1, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 1, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 24, 2021RFNTREFUSAL PROCESSED BY IB—
Dec 30, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 29, 2020RFRRREFUSAL PROCESSED BY MPU—
Dec 15, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 15, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 14, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 11, 2020DOCKASSIGNED TO EXAMINER—
Dec 11, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 10, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance